About Beta Drugs
Beta Drugs is a company based in Panchkula (India) founded in 2005. The company has 382 employees as of March 31, 2025. Beta Drugs offers products and services including Oncology Products, Cosmeceutical Products, API Development, and Contract Manufacturing. Beta Drugs operates in a competitive market with competitors including Jazz Pharmaceuticals, Pharmaron, Revolution Medicines, Blueprint Medicines and Syndax, among others.
- Headquarter Panchkula, India
- Employees 382 as on 31 Mar, 2025
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Beta Drugs Ltd.
-
Annual Revenue
$42.29 M (USD)22.65as on Mar 31, 2024
-
Net Profit
$4.96 M (USD)16.42as on Mar 31, 2024
-
EBITDA
$8.72 M (USD)24.33as on Mar 31, 2024
-
Latest Funding Round
$13.88 M (USD), Post-IPO
Nov 27, 2024
- Investors
-
Employee Count
382
as on Mar 31, 2025
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Beta Drugs
Beta Drugs is a publicly listed company on the NSE with ticker symbol BETA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Beta Drugs
Beta Drugs offers a comprehensive portfolio of products and services, including Oncology Products, Cosmeceutical Products, API Development, and Contract Manufacturing.
Medications for cancer treatment and patient care.
Solutions for skin health and dermatological issues.
Innovation in active pharmaceutical ingredients processes.
Production services for other pharmaceutical companies.
Funding Insights of Beta Drugs
- Total Funding Total Funding
- Total Rounds 1
- Last Round Post-IPO — $13.9M
-
First Round
First Round
(27 Nov 2024)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2024 | Amount | Post-IPO - Beta Drugs | Valuation |
investors |
Investors in Beta Drugs
Beta Drugs has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include HealthQuad.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investment fund focused on innovation and social impact in India.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Beta Drugs
Financial Statements - Beta Drugs
Beta Drugs Comparisons
Competitors of Beta Drugs
Beta Drugs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Pharmaron, Revolution Medicines, Blueprint Medicines and Syndax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Drug discovery and development services for small molecules are provided.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
Frequently Asked Questions about Beta Drugs
Beta Drugs was founded in 2005 and raised its 1st funding round 19 years after it was founded.
Beta Drugs is headquartered in Panchkula, India. It is registered at Panchkula, Haryana, India.
As of Mar 31, 2025, the latest employee count at Beta Drugs is 382.
Annual revenue of Beta Drugs is $42.29M as on Mar 31, 2024.
Beta Drugs was founded in 2005 and is based in Panchkula, India. Therapeutics targeting oncology and dermatology are developed within the pharmaceutical sector. Specific products, including nanoparticle-albumin-bound paclitaxel, docetaxel, and gemcitabine, are offered as tablets, capsules, oral liquids, and injectables. Additional services encompass method development, qualification, validation, transfer, stability protocol creation, pre-formulation studies, and related activities.
Beta Drugs's top competitors include Jazz Pharmaceuticals, Pharmaron and C4 Therapeutics.
Beta Drugs offers Oncology Products, Cosmeceutical Products, API Development, and Contract Manufacturing.
Yes, Beta Drugs is publicly traded on NSE under the ticker symbol BETA.
Beta Drugs has 1 investor. Key investors include HealthQuad.
The ticker symbol of Beta Drugs is BETA on NSE.